1ysx: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
New page: left|200px<br /> <applet load="1ysx" size="450" color="white" frame="true" align="right" spinBox="true" caption="1ysx" /> '''Solution structure of domain 3 from human s...
 
No edit summary
Line 1: Line 1:
[[Image:1ysx.gif|left|200px]]<br />
[[Image:1ysx.gif|left|200px]]<br /><applet load="1ysx" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1ysx" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1ysx" />
caption="1ysx" />
'''Solution structure of domain 3 from human serum albumin complexed to an anti-apoptotic ligand directed against Bcl-xL and Bcl-2'''<br />
'''Solution structure of domain 3 from human serum albumin complexed to an anti-apoptotic ligand directed against Bcl-xL and Bcl-2'''<br />


==Overview==
==Overview==
Proteins in the Bcl-2 family are central regulators of programmed cell, death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are, overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with, chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase, sensitivity to anticancer drugs and enhance in vivo survival. The, development of inhibitors of these proteins as potential anti-cancer, therapeutics has been previously explored, but obtaining potent, small-molecule inhibitors has proved difficult owing to the necessity of, targeting a protein-protein interaction. Here, using nuclear magnetic, resonance (NMR)-based screening, parallel synthesis and structure-based, design, we have discovered ABT-737, a small-molecule inhibitor of the, anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to, three orders of magnitude more potent than previously reported compounds., Mechanistic studies reveal that ABT-737 does not directly initiate the, apoptotic process, but enhances the effects of death signals, displaying, synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737, exhibits single-agent-mechanism-based killing of cells from lymphoma and, small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of, established tumours, and produces cures in a high percentage of the mice.
Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored, but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.


==Disease==
==Disease==
Line 11: Line 10:


==About this Structure==
==About this Structure==
1YSX is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with 4EB as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1YSX OCA].  
1YSX is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=4EB:'>4EB</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1YSX OCA].  


==Reference==
==Reference==
Line 17: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Armstrong, R.C.]]
[[Category: Armstrong, R C.]]
[[Category: Augeri, D.J.]]
[[Category: Augeri, D J.]]
[[Category: Belli, B.A.]]
[[Category: Belli, B A.]]
[[Category: Bruncko, M.]]
[[Category: Bruncko, M.]]
[[Category: Connor, J.M.O.]]
[[Category: Connor, J M.O.]]
[[Category: Deckwerth, T.L.]]
[[Category: Deckwerth, T L.]]
[[Category: Dinges, J.]]
[[Category: Dinges, J.]]
[[Category: Elmore, S.W.]]
[[Category: Elmore, S W.]]
[[Category: Fesik, S.W.]]
[[Category: Fesik, S W.]]
[[Category: Hajduk, P.J.]]
[[Category: Hajduk, P J.]]
[[Category: Joseph, M.K.]]
[[Category: Joseph, M K.]]
[[Category: Kitada, S.]]
[[Category: Kitada, S.]]
[[Category: Korsmeyer, S.J.]]
[[Category: Korsmeyer, S J.]]
[[Category: Kunzer, A.R.]]
[[Category: Kunzer, A R.]]
[[Category: Letai, A.]]
[[Category: Letai, A.]]
[[Category: Li, C.]]
[[Category: Li, C.]]
[[Category: Mitten, M.J.]]
[[Category: Mitten, M J.]]
[[Category: Nettesheim, D.G.]]
[[Category: Nettesheim, D G.]]
[[Category: Ng, S.]]
[[Category: Ng, S.]]
[[Category: Nimmer, P.M.]]
[[Category: Nimmer, P M.]]
[[Category: Oleksijew, A.]]
[[Category: Oleksijew, A.]]
[[Category: Oltersdorf, T.]]
[[Category: Oltersdorf, T.]]
[[Category: Petros, A.M.]]
[[Category: Petros, A M.]]
[[Category: Reed, J.C.]]
[[Category: Reed, J C.]]
[[Category: Rosenberg, S.H.]]
[[Category: Rosenberg, S H.]]
[[Category: Shen, W.]]
[[Category: Shen, W.]]
[[Category: Shoemaker, A.R.]]
[[Category: Shoemaker, A R.]]
[[Category: Tahir, S.K.]]
[[Category: Tahir, S K.]]
[[Category: Thompson, C.B.]]
[[Category: Thompson, C B.]]
[[Category: Tomaselli, K.J.]]
[[Category: Tomaselli, K J.]]
[[Category: Wang, B.]]
[[Category: Wang, B.]]
[[Category: Wendt, M.D.]]
[[Category: Wendt, M D.]]
[[Category: Zhang, H.]]
[[Category: Zhang, H.]]
[[Category: 4EB]]
[[Category: 4EB]]
[[Category: complex]]
[[Category: complex]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 20:24:21 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:08:42 2008''

Revision as of 17:08, 21 February 2008

File:1ysx.gif


1ysx

Drag the structure with the mouse to rotate

Solution structure of domain 3 from human serum albumin complexed to an anti-apoptotic ligand directed against Bcl-xL and Bcl-2

OverviewOverview

Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored, but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.

DiseaseDisease

Known diseases associated with this structure: Analbuminemia OMIM:[103600], Dysalbuminemic hyperthyroxinemia OMIM:[103600], Dysalbuminemic hyperzincemia OMIM:[103600]

About this StructureAbout this Structure

1YSX is a Single protein structure of sequence from Homo sapiens with as ligand. Full crystallographic information is available from OCA.

ReferenceReference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours., Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15. PMID:15902208

Page seeded by OCA on Thu Feb 21 16:08:42 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA